Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

International Guideline Harmonization Group ototoxicity group

doi:10.1016/S1470-2045(18)30858-1

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

International Guideline Harmonization Group ototoxicity group

Klinik für Kinder- und Jugendmedizin

Erasmus Medical College
Princess Máxima Center for Pediatric Oncology
University of Amsterdam
St. Jude Children Research Hospital
Newcastle University
University of Rochester Medical Center
University of Bern
Kepler University Hospital
Université Lille-Nord de France
Great Ormond Street Hospital for Children NHS Foundation Trust
University of British Columbia
Stanford University
Sydney Children's Hospital
The Hospital for Sick Children
Keck School of Medicine of USC
University Hospital Brno
University of Basel
Universität Westaustralien
Universität Regensburg
Westfälische Wilhelms-Universität Münster
Macquarie University, Australian School of Advanced Medicine
University of Alabama

129 Zitate (Scopus)

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Originalsprache	Englisch
Zeitschrift	The Lancet Oncology
Jahrgang	20
Ausgabenummer	1
Seiten (von - bis)	29-41
Seitenumfang	13
ISSN	1470-2045
DOIs	https://doi.org/10.1016/S1470-2045(18)30858-1
Publikationsstatus	Veröffentlicht - 01.2019

Fördermittel

We thank the following experts of the International Late Effects of Childhood Cancer Guideline Harmonization Group and other members for their participation in the international guideline harmonization process: Nina Kadan-Lottick, Gill Levitt, Alex Hoetink, John Mussman, and Aimilia Tsirou for critically appraising the recommendations and manuscript. We would like to thank the PanCareLIFE consortium. We also thank the National Cancer Institute for supporting the work of the Children's Oncology Group ( National Clinical Trials Network Group Operations Center Grant U10CA180886 ). ECvD reports grants from Stichting Kinderen Kankervrij during the study. PRB reports personal fees from Fennec Pharmaceuticals outside the submitted work. EC, AaZD, RS, MMvdHE, RLM, and LCK received support from the 7th Framework Programme of the EU (PanCareLIFE). MMH is supported by a Cancer Center Support grant (CA21765) to St Jude Children's Research Hospital and the American Lebanese Syrian Associated Charities. RLM received funding from the Dutch Cancer Society. AW received support from the Swiss Cancer League. KK is supported by a Veteran Affairs Merit Review Grant and US National Institutes of Health. The remaining authors have nothing to declare.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Zugriff auf Dokument

10.1016/S1470-2045(18)30858-1

Andere Dateien und Links

Link to publication in Scopus

Fingerprint

Untersuchen Sie die Forschungsthemen von „Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren

International Guideline Harmonization Group ototoxicity group (2019). Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. The Lancet Oncology, 20(1), 29-41. https://doi.org/10.1016/S1470-2045(18)30858-1

International Guideline Harmonization Group ototoxicity group. / Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. in: The Lancet Oncology. 2019 ; Jahrgang 20, Nr. 1. S. 29-41.

@article{510e6b87aa5b4ec6b500e0826f2d16e8,

title = "Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium",

abstract = "Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems{\textemdash}such as speech and language, social{\textendash}emotional development, and learning difficulties{\textemdash}for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.",

author = "\{International Guideline Harmonization Group ototoxicity group\} and Eva Clemens and \{van den Heuvel-Eibrink\}, \{Marry M.\} and Mulder, \{Ren{\'e}e L.\} and Kremer, \{Leontien C.M.\} and Hudson, \{Melissa M.\} and Roderick Skinner and Constine, \{Louis S.\} and Bass, \{Johnnie K.\} and Kuehni, \{Claudia E.\} and Thorsten Langer and \{van Dalen\}, \{Elvira C.\} and Edith Bardi and Bonne, \{Nicolas Xavier\} and Brock, \{Penelope R.\} and Beth Brooks and Bruce Carleton and Eric Caron and Chang, \{Kay W.\} and Karen Johnston and Kristin Knight and Nathan, \{Paul C.\} and Etan Orgel and Prasad, \{Pinki K.\} and Jan Rottenberg and Katrin Scheinemann and \{de Vries\}, \{Andrica C.H.\} and Thomas Walwyn and Annette Weiss and \{am Zehnhoff-Dinnesen\}, Antoinette and Cohn, \{Richard J.\} and Wendy Landier",

note = "Funding Information: We thank the following experts of the International Late Effects of Childhood Cancer Guideline Harmonization Group and other members for their participation in the international guideline harmonization process: Nina Kadan-Lottick, Gill Levitt, Alex Hoetink, John Mussman, and Aimilia Tsirou for critically appraising the recommendations and manuscript. We would like to thank the PanCareLIFE consortium. We also thank the National Cancer Institute for supporting the work of the Children's Oncology Group ( National Clinical Trials Network Group Operations Center Grant U10CA180886 ). Funding Information: ECvD reports grants from Stichting Kinderen Kankervrij during the study. PRB reports personal fees from Fennec Pharmaceuticals outside the submitted work. EC, AaZD, RS, MMvdHE, RLM, and LCK received support from the 7th Framework Programme of the EU (PanCareLIFE). MMH is supported by a Cancer Center Support grant (CA21765) to St Jude Children's Research Hospital and the American Lebanese Syrian Associated Charities. RLM received funding from the Dutch Cancer Society. AW received support from the Swiss Cancer League. KK is supported by a Veteran Affairs Merit Review Grant and US National Institutes of Health. The remaining authors have nothing to declare. Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = jan,

doi = "10.1016/S1470-2045(18)30858-1",

language = "English",

volume = "20",

pages = "29--41",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "1",

}

International Guideline Harmonization Group ototoxicity group 2019, 'Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium', The Lancet Oncology, Jg. 20, Nr. 1, S. 29-41. https://doi.org/10.1016/S1470-2045(18)30858-1

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. / International Guideline Harmonization Group ototoxicity group.
in: The Lancet Oncology, Jahrgang 20, Nr. 1, 01.2019, S. 29-41.

Publikation: Beiträge in Fachzeitschriften › Übersichtsarbeiten › Forschung

TY - JOUR

T1 - Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

AU - International Guideline Harmonization Group ototoxicity group

AU - Clemens, Eva

AU - van den Heuvel-Eibrink, Marry M.

AU - Mulder, Renée L.

AU - Kremer, Leontien C.M.

AU - Hudson, Melissa M.

AU - Skinner, Roderick

AU - Constine, Louis S.

AU - Bass, Johnnie K.

AU - Kuehni, Claudia E.

AU - Langer, Thorsten

AU - van Dalen, Elvira C.

AU - Bardi, Edith

AU - Bonne, Nicolas Xavier

AU - Brock, Penelope R.

AU - Brooks, Beth

AU - Carleton, Bruce

AU - Caron, Eric

AU - Chang, Kay W.

AU - Johnston, Karen

AU - Knight, Kristin

AU - Nathan, Paul C.

AU - Orgel, Etan

AU - Prasad, Pinki K.

AU - Rottenberg, Jan

AU - Scheinemann, Katrin

AU - de Vries, Andrica C.H.

AU - Walwyn, Thomas

AU - Weiss, Annette

AU - am Zehnhoff-Dinnesen, Antoinette

AU - Cohn, Richard J.

AU - Landier, Wendy

N1 - Funding Information: We thank the following experts of the International Late Effects of Childhood Cancer Guideline Harmonization Group and other members for their participation in the international guideline harmonization process: Nina Kadan-Lottick, Gill Levitt, Alex Hoetink, John Mussman, and Aimilia Tsirou for critically appraising the recommendations and manuscript. We would like to thank the PanCareLIFE consortium. We also thank the National Cancer Institute for supporting the work of the Children's Oncology Group ( National Clinical Trials Network Group Operations Center Grant U10CA180886 ). Funding Information: ECvD reports grants from Stichting Kinderen Kankervrij during the study. PRB reports personal fees from Fennec Pharmaceuticals outside the submitted work. EC, AaZD, RS, MMvdHE, RLM, and LCK received support from the 7th Framework Programme of the EU (PanCareLIFE). MMH is supported by a Cancer Center Support grant (CA21765) to St Jude Children's Research Hospital and the American Lebanese Syrian Associated Charities. RLM received funding from the Dutch Cancer Society. AW received support from the Swiss Cancer League. KK is supported by a Veteran Affairs Merit Review Grant and US National Institutes of Health. The remaining authors have nothing to declare. Publisher Copyright: © 2019 Elsevier Ltd Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/1

Y1 - 2019/1

N2 - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

AB - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

UR - https://www.scopus.com/pages/publications/85059341149

U2 - 10.1016/S1470-2045(18)30858-1

DO - 10.1016/S1470-2045(18)30858-1

M3 - Scientific review articles

C2 - 30614474

AN - SCOPUS:85059341149

SN - 1470-2045

VL - 20

SP - 29

EP - 41

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 1

ER -

International Guideline Harmonization Group ototoxicity group. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. The Lancet Oncology. 2019 Jan.;20(1):29-41. doi: 10.1016/S1470-2045(18)30858-1